A neurotropic approach to the treatment of multi-infarct dementia using l-a-glycerylphosphorylcholine
A multicenter, unblinded, randomized, controlled clinical trial was conducted to evaluate the efficacy and tolerability of L-aglycerylphosphorylcholine (L-a-GPC) 1 gm/day IM compared with that of cytidine diphosphocholine (CDP-choline) 1 gm/day IM in 112 patients with mild to moderate multi-infarct...
Main Authors: | , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Federal State Budget Scientific Institution National Medical Research Center for Psychiatry and Neurology n.a. V.M. Bekhterev Ministry of Health of the Russian Federation
2018-07-01
|
Series: | Обозрение психиатрии и медицинской психологии имени В.М. Бехтерева |
Subjects: | |
Online Access: | https://www.bekhterevreview.com/jour/article/view/17 |
_version_ | 1797694448852795392 |
---|---|
author | Alberto Muratorio Ubaldo Bonuccelli Angelo Nuti Noe Bavpistini Stefano Passero Vittoria Caruso Barbara Batani Alberto Baroni Federico Mayer Tiziana Sorbi Attilio Franciosi Gianni Moro Luciano Agostini Massimo Piccirilli Diana Scatozza |
author_facet | Alberto Muratorio Ubaldo Bonuccelli Angelo Nuti Noe Bavpistini Stefano Passero Vittoria Caruso Barbara Batani Alberto Baroni Federico Mayer Tiziana Sorbi Attilio Franciosi Gianni Moro Luciano Agostini Massimo Piccirilli Diana Scatozza |
author_sort | Alberto Muratorio |
collection | DOAJ |
description | A multicenter, unblinded, randomized, controlled clinical trial was conducted to evaluate the efficacy and tolerability of L-aglycerylphosphorylcholine (L-a-GPC) 1 gm/day IM compared with that of cytidine diphosphocholine (CDP-choline) 1 gm/day IM in 112 patients with mild to moderate multi-infarct dementia. A 90-day treatment period with the test drug was followed by a 90-day follow-up period without treatment to observe how long the results obtained with treatment could be maintained. A total of 97 patients completed the treatment period; of these, 73 completed the follow-up period. Eighteen patients did not complete the study because of poor compliance, and 21 patients at one center were not followed up. Treatments were started after a 2-week washout period during which other drugs that could affect cognitive function were withdrawn. Clinical efficacy was evaluated by comparing the results at baseline, after 30 days, at the end of treatment, and at the end of the follow-up period on the following psychometric tests: the Sandoz Clinical Assessment Geriatric (SCAG) Rating Scale, the Blessed Dementia Scale, the Blessed Information, Memory, Concentration test, the Wechsler Memory Scale (WMS), the Rapid Disability Rating Scale 2 (RDRS 2), the Word Fluency test, the Token test, and the Simple Drawing Copy (SDC). The patients receiving L-a-GPC showed a significant improvement of cognitive functions, behaviour, and personality at the end of the treatment, compared with baseline values. This improvement was still apparent at the end of the follow-up period. A comparison of the results obtained with L-a-GPC and CDP-choline shows that the performance of the patients treated with L-a-GPC was significantly better than that of the CDP-choline group on the Blessed Dementia Scale, WMS, RDRS 2, and SDC at the end of treatment and on the Blessed Dementia Scale, WMS, SCAG, and Token test at the end of the follow-up period. |
first_indexed | 2024-03-12T02:58:07Z |
format | Article |
id | doaj.art-7f37ad910a314e839020d3852a333550 |
institution | Directory Open Access Journal |
issn | 2313-7053 2713-055X |
language | Russian |
last_indexed | 2024-03-12T02:58:07Z |
publishDate | 2018-07-01 |
publisher | Federal State Budget Scientific Institution National Medical Research Center for Psychiatry and Neurology n.a. V.M. Bekhterev Ministry of Health of the Russian Federation |
record_format | Article |
series | Обозрение психиатрии и медицинской психологии имени В.М. Бехтерева |
spelling | doaj.art-7f37ad910a314e839020d3852a3335502023-09-03T15:08:43ZrusFederal State Budget Scientific Institution National Medical Research Center for Psychiatry and Neurology n.a. V.M. Bekhterev Ministry of Health of the Russian FederationОбозрение психиатрии и медицинской психологии имени В.М. Бехтерева2313-70532713-055X2018-07-0102536017A neurotropic approach to the treatment of multi-infarct dementia using l-a-glycerylphosphorylcholineAlberto Muratorio0Ubaldo Bonuccelli1Angelo Nuti2Noe Bavpistini3Stefano Passero4Vittoria Caruso5Barbara Batani6Alberto Baroni7Federico Mayer8Tiziana Sorbi9Attilio Franciosi10Gianni Moro11Luciano Agostini12Massimo Piccirilli13Diana Scatozza14Istituto di Clinica Neurologica, Universita di PisaIstituto di Clinica Neurologica, Universita di PisaIstituto di Clinica delle Malattie Nervose e Mentali, Universita di SienaIstituto di Clinica delle Malattie Nervose e Mentali, Universita di SienaIstituto di Clinica delle Malattie Nervose e Mentali, Universita di SienaIstituto di Clinica delle Malattie Nervose e Mentali, Universita di SienaCentro di Geriatria Fraticini, I.N.R.C.A., FirenzeCentro di Geriatria Fraticini, I.N.R.C.A., FirenzeCentro di Geriatria Fraticini, I.N.R.C.A., FirenzeCentro di Geriatria Fraticini, I.N.R.C.A., FirenzeServizio di Neurologia, Ospedale Civile di ArzignanoServizio di Neurologia, Ospedale Civile di ArzignanoClinica Neurologica, Universita di PerugiaClinica Neurologica, Universita di PerugiaDirezione Medico Scientifica, Italfarmaco S.p.AA multicenter, unblinded, randomized, controlled clinical trial was conducted to evaluate the efficacy and tolerability of L-aglycerylphosphorylcholine (L-a-GPC) 1 gm/day IM compared with that of cytidine diphosphocholine (CDP-choline) 1 gm/day IM in 112 patients with mild to moderate multi-infarct dementia. A 90-day treatment period with the test drug was followed by a 90-day follow-up period without treatment to observe how long the results obtained with treatment could be maintained. A total of 97 patients completed the treatment period; of these, 73 completed the follow-up period. Eighteen patients did not complete the study because of poor compliance, and 21 patients at one center were not followed up. Treatments were started after a 2-week washout period during which other drugs that could affect cognitive function were withdrawn. Clinical efficacy was evaluated by comparing the results at baseline, after 30 days, at the end of treatment, and at the end of the follow-up period on the following psychometric tests: the Sandoz Clinical Assessment Geriatric (SCAG) Rating Scale, the Blessed Dementia Scale, the Blessed Information, Memory, Concentration test, the Wechsler Memory Scale (WMS), the Rapid Disability Rating Scale 2 (RDRS 2), the Word Fluency test, the Token test, and the Simple Drawing Copy (SDC). The patients receiving L-a-GPC showed a significant improvement of cognitive functions, behaviour, and personality at the end of the treatment, compared with baseline values. This improvement was still apparent at the end of the follow-up period. A comparison of the results obtained with L-a-GPC and CDP-choline shows that the performance of the patients treated with L-a-GPC was significantly better than that of the CDP-choline group on the Blessed Dementia Scale, WMS, RDRS 2, and SDC at the end of treatment and on the Blessed Dementia Scale, WMS, SCAG, and Token test at the end of the follow-up period.https://www.bekhterevreview.com/jour/article/view/17сосудистая деменциямультиинфарктная деменциянейропротективное действиекогнитивная функцияхолинацетилхолинхолина альфосцератvascular dementiamulti-infarct dementianeuroprotectiv actioncognitive functioncholineacetylcholinecholine alfostserat |
spellingShingle | Alberto Muratorio Ubaldo Bonuccelli Angelo Nuti Noe Bavpistini Stefano Passero Vittoria Caruso Barbara Batani Alberto Baroni Federico Mayer Tiziana Sorbi Attilio Franciosi Gianni Moro Luciano Agostini Massimo Piccirilli Diana Scatozza A neurotropic approach to the treatment of multi-infarct dementia using l-a-glycerylphosphorylcholine Обозрение психиатрии и медицинской психологии имени В.М. Бехтерева сосудистая деменция мультиинфарктная деменция нейропротективное действие когнитивная функция холин ацетилхолин холина альфосцерат vascular dementia multi-infarct dementia neuroprotectiv action cognitive function choline acetylcholine choline alfostserat |
title | A neurotropic approach to the treatment of multi-infarct dementia using l-a-glycerylphosphorylcholine |
title_full | A neurotropic approach to the treatment of multi-infarct dementia using l-a-glycerylphosphorylcholine |
title_fullStr | A neurotropic approach to the treatment of multi-infarct dementia using l-a-glycerylphosphorylcholine |
title_full_unstemmed | A neurotropic approach to the treatment of multi-infarct dementia using l-a-glycerylphosphorylcholine |
title_short | A neurotropic approach to the treatment of multi-infarct dementia using l-a-glycerylphosphorylcholine |
title_sort | neurotropic approach to the treatment of multi infarct dementia using l a glycerylphosphorylcholine |
topic | сосудистая деменция мультиинфарктная деменция нейропротективное действие когнитивная функция холин ацетилхолин холина альфосцерат vascular dementia multi-infarct dementia neuroprotectiv action cognitive function choline acetylcholine choline alfostserat |
url | https://www.bekhterevreview.com/jour/article/view/17 |
work_keys_str_mv | AT albertomuratorio aneurotropicapproachtothetreatmentofmultiinfarctdementiausinglaglycerylphosphorylcholine AT ubaldobonuccelli aneurotropicapproachtothetreatmentofmultiinfarctdementiausinglaglycerylphosphorylcholine AT angelonuti aneurotropicapproachtothetreatmentofmultiinfarctdementiausinglaglycerylphosphorylcholine AT noebavpistini aneurotropicapproachtothetreatmentofmultiinfarctdementiausinglaglycerylphosphorylcholine AT stefanopassero aneurotropicapproachtothetreatmentofmultiinfarctdementiausinglaglycerylphosphorylcholine AT vittoriacaruso aneurotropicapproachtothetreatmentofmultiinfarctdementiausinglaglycerylphosphorylcholine AT barbarabatani aneurotropicapproachtothetreatmentofmultiinfarctdementiausinglaglycerylphosphorylcholine AT albertobaroni aneurotropicapproachtothetreatmentofmultiinfarctdementiausinglaglycerylphosphorylcholine AT federicomayer aneurotropicapproachtothetreatmentofmultiinfarctdementiausinglaglycerylphosphorylcholine AT tizianasorbi aneurotropicapproachtothetreatmentofmultiinfarctdementiausinglaglycerylphosphorylcholine AT attiliofranciosi aneurotropicapproachtothetreatmentofmultiinfarctdementiausinglaglycerylphosphorylcholine AT giannimoro aneurotropicapproachtothetreatmentofmultiinfarctdementiausinglaglycerylphosphorylcholine AT lucianoagostini aneurotropicapproachtothetreatmentofmultiinfarctdementiausinglaglycerylphosphorylcholine AT massimopiccirilli aneurotropicapproachtothetreatmentofmultiinfarctdementiausinglaglycerylphosphorylcholine AT dianascatozza aneurotropicapproachtothetreatmentofmultiinfarctdementiausinglaglycerylphosphorylcholine AT albertomuratorio neurotropicapproachtothetreatmentofmultiinfarctdementiausinglaglycerylphosphorylcholine AT ubaldobonuccelli neurotropicapproachtothetreatmentofmultiinfarctdementiausinglaglycerylphosphorylcholine AT angelonuti neurotropicapproachtothetreatmentofmultiinfarctdementiausinglaglycerylphosphorylcholine AT noebavpistini neurotropicapproachtothetreatmentofmultiinfarctdementiausinglaglycerylphosphorylcholine AT stefanopassero neurotropicapproachtothetreatmentofmultiinfarctdementiausinglaglycerylphosphorylcholine AT vittoriacaruso neurotropicapproachtothetreatmentofmultiinfarctdementiausinglaglycerylphosphorylcholine AT barbarabatani neurotropicapproachtothetreatmentofmultiinfarctdementiausinglaglycerylphosphorylcholine AT albertobaroni neurotropicapproachtothetreatmentofmultiinfarctdementiausinglaglycerylphosphorylcholine AT federicomayer neurotropicapproachtothetreatmentofmultiinfarctdementiausinglaglycerylphosphorylcholine AT tizianasorbi neurotropicapproachtothetreatmentofmultiinfarctdementiausinglaglycerylphosphorylcholine AT attiliofranciosi neurotropicapproachtothetreatmentofmultiinfarctdementiausinglaglycerylphosphorylcholine AT giannimoro neurotropicapproachtothetreatmentofmultiinfarctdementiausinglaglycerylphosphorylcholine AT lucianoagostini neurotropicapproachtothetreatmentofmultiinfarctdementiausinglaglycerylphosphorylcholine AT massimopiccirilli neurotropicapproachtothetreatmentofmultiinfarctdementiausinglaglycerylphosphorylcholine AT dianascatozza neurotropicapproachtothetreatmentofmultiinfarctdementiausinglaglycerylphosphorylcholine |